Oncology
Thomas Helleday, PhD, Professor Karolinska Institutet, Sweden, where he heads a large multidisciplinary translational research group focusing on understanding DNA damage response biology and translating the findings into novel anti-cancer treatments concepts and drugs. Chairman of the SAB.
Giorgio Massimini, MD, PhD. Dr. Massimini has dedicated his career to oncology clinical development. He was responsible for clinical trials of Roferon-A, Interleukin 2, and G-CSF, leading to international marketing approvals for Roferon-A. He was recently retired from his position as Vice President, Head Medical Officer at Merck Biopharma.
Andrea Wahner Hendriksson, MD, PhD, Associate Professor of Oncology, Mayo clinical, Chester Minnesota. Dr. Wahner is a clinical-investigator and part of the Mayo Clinic Phase 1 group and the NIH-funded Mayo Clinic Ovarian Cancer Specialized Program of research Excellence (SPORE) grant.
Sarah Danson, MD, PhD, deputy Director, Weston Park cancer Centre. Dr Danson is a medical oncologist, and chair of the Adult ECMC Network UK. She is Weston Park Cancer Centre Deputy Director and NHR National Specialty Lead for Cancer Early clinical Phase.
Mikael von Euler, MD, PHD, EFPM. Dr. von Euler is an oncologist with > 30 years of experience in the pharmaceutical industry, e.g. as Cluster Head for the Her2 area (Herceptin, pertuzumab, T-DM1) at Roche/Genentech, Vice President of Oncology Europe at GlaxoSmithKline and Global Production Director of Arimidex/Nolvadex at AstraZeneca.
Idiopathic Pulmonary Fibrosis
Andreas Günther, MD, PhD, is a Professor at the Justus-Liebig University Giessen, where he leads the Center for Interstitial and Rare Diseases. He has published over 200 peer-reviewed articles, received prestigious awards including the Heisenberg and Oscar Medicine Prize. He is a board-certified specialist in Internal Medicine, Pulmonology, Critical Care, and Sleep Medicine, based at the University Hospital Giessen & Marburg and the Lung Clinic at the AGAPLESION Evangelisches Krankenhaus Mittelhessen, both in Giessen. He is the Lead Coordinator of the European ILD Registry and Biobank (eurILDreg), a major international initiative to advance diagnostics, biomarker discovery, and personalized therapies for interstitial lung diseases (ILDs).
Elisabeth Bendstrup, MD, PhD, is professor at the Department of Respiratory Diseases and Allergy, Aarhus University Hospital, and Department of Clinical Medicine, Aarhus University, Denmark. Prof. Bendstrup is head of Center for Rare Lung Disease, the hospital unit for interstitial lung diseases and is clinical investigator and respiratory research lead. She combines her clinical work with research and is principal investigator in several national and international ILD clinical trials. Her research focuses mainly on pulmonary fibrosis and ultrarare lung diseases and she has published more than 250 peer-reviewed articles and has been a member of several international guideline task forces.
Jesper M. Magnusson, MD, PhD, is senior physician and associate professor at Sahlgrenska Department of Lung Medicine and Sahlgrenska Transplantation Centre at Sahlgrenska University Hospital in Gothenburg, Sweden. He combines clinical expertise with translational research. After his dissertation in 2018 he has focused on advancing patient care through both academic medicine and clinical practice. His research interests bridge bench to bedside in Pulmonary fibrosis and Lung transplantation, with an emphasis on improving outcomes and integrating novel scientific findings into everyday healthcare. Dr Magnusson also has startup corporate experience as a board member of Mucolife Therapeutics.
Martin Kolb, M.D, PhD, is Professor in the Division of Respirology at McMaster University and Research Director at the Firestone Institute for Respiratory Health in Canada. He is an internationally recognised clinician-scientist specializing in interstitial lung disease (ILD), particularly idiopathic pulmonary fibrosis (IPF), with 350 peer-reviewed articles and has received prestigious awards. In 2024, Dr. Kolb was elected as a Fellow of the Canadian Academy of Health Sciences, one of the highest honours for Canadian healthcare researchers. He is the immediate past Chief Editor of the European Respiratory Journal and currently serves as Section Editor for ILD. He is a Principal Investigator and Steering Committee member in several national and international ILD clinical trials.